progression-free survival
Fig. 3 · Panel progression-free_survival_PFS_
Panel progression-free_survival_PFS_ 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Jin Seok Kim, Yang Song, Wei-Ying Jen, C S Chim, Je-Jung Lee, Sung-Soo Yoon, Soo Chin Ng, Gin Gin Gan, Hiroshi Handa, Jae Hoon Lee, Kihyun Kim, Shigeki Ito, Jeffrey Shang-Yi Huang, Chang Ki Min, Melissa Ooi Gaik Ming, Sanjay de Mel, Cinnie Soekojo, Xinhua Li, Neha Awasthi, Yogesh Pokharkar, Brian Gm Durie, Wee-Joo Chng
Blood Cancer J 15(1) 155
Pomalidomide has been shown to improve survival in patients with relapsed/refractory myeloma (RRMM). However, the optimal pomalidomide-based combinations in RRMM are not known. This study compared pomalidomide, cyclophosphamide, dexamethasone (PCD) with pomalidomide and dexamethasone (PD) in Asian patients with RRMM. Patients were randomly assigned to receive PCD or PD. Patients received pomalidomide at 4 mg from days 1 to 21, dexamethasone at 40 mg once a week, and those in the PCD arm received cyclophosphamide at 400 mg once weekly for three weeks. The primary endpoint was progression-free survival. One hundred and twenty-two patients were randomized (62 PCD, 60 PD). Baseline characteristics were comparable between both arms. The median prior lines of therapy were three. At a median follow-up of 13.5 (median range 9-18) months, median progression free survival was significantly longer at 10.9 months (95% confidence interval 7.1-27.7) in the PCD group compared with 5.8 months (95% CI, 4.4-6.9) in the PD group (hazard ratio 0.43; p < 0.001). Adverse events rates were similar in both arms. The most common grade ≥3 adverse events were hematological toxicities and pneumonia. 34 deaths occurred during the study (PCD: 17; PD: 17) and three were deemed to be related to study treatment. In Asian patients with RRMM after exposure to proteasome inhibitor and lenalidomide, progression-free survival was significantly prolonged with the addition of cyclophosphamide to PD, with a manageable safety profile.Trial ID: Registered at www.clinicaltrials.gov : NCT03143049.
3 个 Figure · 3 个 KM 面板
Fig. 3 Kaplan-Meier curves of the mITT population for progression-free survival (PFS).
Fig. 3 · Panel progression-free_survival_PFS_
Panel progression-free_survival_PFS_ 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 Kaplan-Meier curves of the mITT population for duration of response (DOR).
Fig. 4 · Panel DOR
Panel DOR 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 6 Kaplan-Meier curves of the mITT population for Overall Survival (OS).
Fig. 6 · Panel Overall_Survival
Panel Overall_Survival 是同一 Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。